Not testing for LB positivity when including participants in such AD trials could hamper the ability to detect effects of anti-Aβ or anti-tau treatments on cognitive decline and could potentially be one of several causes for continuous cognitive decline despite complete removal of Aβ from the brain in AD participants23,24. This evidence concerns the gene MAPT and Alzheimer disease.